Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Down 68.8% in January

Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) saw a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 272,000 shares, a drop of 68.8% from the January 15th total of 872,900 shares. Currently, 0.5% of the shares of the company are short sold. Based on an average daily volume of 142,600 shares, the days-to-cover ratio is presently 1.9 days.

Analyst Ratings Changes

Separately, The Goldman Sachs Group lowered Nautilus Biotechnology from a "neutral" rating to a "sell" rating and lowered their price target for the stock from $2.25 to $1.75 in a report on Thursday, December 5th.

Hedge Funds Weigh In On Nautilus Biotechnology

A number of hedge funds and other institutional investors have recently made changes to their positions in NAUT. SG Americas Securities LLC purchased a new position in shares of Nautilus Biotechnology during the third quarter worth about $50,000. China Universal Asset Management Co. Ltd. boosted its holdings in Nautilus Biotechnology by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company's stock valued at $69,000 after purchasing an additional 9,404 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in Nautilus Biotechnology in the 3rd quarter valued at approximately $67,000. MetLife Investment Management LLC purchased a new stake in Nautilus Biotechnology in the 3rd quarter valued at approximately $87,000. Finally, Wexford Capital LP boosted its holdings in Nautilus Biotechnology by 9.6% in the 3rd quarter. Wexford Capital LP now owns 228,350 shares of the company's stock valued at $651,000 after purchasing an additional 20,000 shares in the last quarter. Hedge funds and other institutional investors own 50.71% of the company's stock.

Nautilus Biotechnology Trading Down 0.6 %

Shares of NASDAQ NAUT traded down $0.01 during midday trading on Friday, reaching $1.71. 39,828 shares of the company were exchanged, compared to its average volume of 96,122. Nautilus Biotechnology has a 1 year low of $1.56 and a 1 year high of $3.10. The stock has a fifty day simple moving average of $1.81 and a 200 day simple moving average of $2.31. The stock has a market cap of $214.71 million, a P/E ratio of -3.05 and a beta of 1.21.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.